Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a
leading producer of critical reagents for the discovery,
development, and commercialization of novel therapies, vaccines,
and molecular diagnostics, today announced financial results for
the first quarter ended March 31, 2024.
“I am pleased with our performance in the first quarter,” said
Stephen Gunstream, President and Chief Executive Officer at
Teknova. “Not only did we deliver solid results, but we
successfully introduced our latest product innovation –
Build-Tek™ Solutions – developed specifically to enable
scientists to receive multiple discrete buffer formulations in a
matter of days for use during early-stage therapy development. We
believe this first-of-its-kind, custom solution will enable our
customers to focus on advancing science instead of spending their
time on buffer production,” he added.
“During the first quarter of 2024, we delivered strong results
overall and managed our operating expenses and capital expenditures
to our plan. The combination of these results and improved order
trends further strengthens our belief in our full-year outlook of
$35-38 million of revenue and free cash outflow of less than $18
million,” explained Matt Lowell, Teknova’s Chief Financial
Officer.
Corporate and Financial Updates
- First quarter 2024 total revenue of
$9.3 million, up 2% from the first quarter 2023
- Launched Build-Tek Solutions, an online
custom configurator that supports the fast turnaround of multiple,
discrete buffer formulations for use during early-stage research
and design of experiments (DOE)
- Introduced the latest product in our
proprietary AAV-TekTM Solutions product line – the AAV-Tek AAV
Stabilizer – a novel, multi-purpose solution that increases capsid
yield up to 50% while safeguarding product integrity across the AAV
purification workflow
- Cash position of $21.6 million and
gross debt of $12.1 million at the end of the first quarter
2024
Revenue for the First Quarter
|
For the Three Months Ended March
31, |
|
(Dollars in
thousands) |
2024 |
|
|
2023 |
|
Lab Essentials |
$ |
7,266 |
|
|
$ |
7,257 |
|
Clinical
Solutions |
|
1,718 |
|
|
|
1,609 |
|
Other |
|
306 |
|
|
|
255 |
|
Total
revenue |
$ |
9,290 |
|
|
$ |
9,121 |
|
|
|
|
|
|
|
|
|
First Quarter 2024 Financial Results
Total revenue for the first quarter 2024 was $9.3 million, up 2%
compared to $9.1 million in the first quarter 2023. Lab Essentials
revenue was $7.3 million in the first quarter 2024, flat compared
to $7.3 million in the first quarter 2023. Clinical Solutions
revenue was $1.7 million in the first quarter 2024, up 7% compared
to $1.6 million in the first quarter 2023.
Gross profit for the first quarter 2024 was $2.2 million,
compared to $2.4 million in the first quarter 2023. Gross margin
for the first quarter 2024 was 23.8%, compared to 26.6% in the
first quarter 2023. The decrease in gross profit percentage was
driven primarily by increased overhead costs, largely depreciation
expense, following the completion of our new manufacturing facility
in mid-2023, partially offset by reduced headcount.
Operating expenses for the first quarter 2024 were $10.2
million, compared to $11.4 million in the first quarter 2023.
Excluding the non-recurring charges recorded in the first quarter
of 2024 and 2023 of $1.3 million and $0.7 million, respectively,
each related to a reduction in workforce, operating expenses were
down $1.7 million. The decrease was driven primarily by reduced
headcount and spending, in particular in professional fees.
Net loss for the first quarter 2024 was $8.1 million, or
negative $0.20 per diluted share, compared to $8.8 million, or
negative $0.31 per diluted share, for the first quarter 2023.
Adjusted EBITDA for the first quarter 2024 was negative $3.8
million, compared to negative $6.1 million for the first quarter
2023. Free Cash Flow was negative $6.7 million for the first
quarter 2024, compared to negative $12.0 million for the first
quarter 2023. A full reconciliation of these non-GAAP measures to
the most comparable GAAP measures is included at the end of this
release.
Reiterates 2024 Outlook
Teknova is reiterating its fiscal 2024 outlook for revenue and
free cash outflow. The Company continues to anticipate total
revenue of $35 million to $38 million for the fiscal year ending
December 31, 2024 (“2024”), which assumes roughly 10% growth in Lab
Essentials and the remaining revenue from Clinical Solutions. The
Company also continues to anticipate free cash outflow of less than
$18 million for 2024.
Upcoming Investor Conference Attendance
William Blair 44th Annual Growth Stock ConferenceChicago,
Illinois, fromJune 4 - 6, 2024
Conference Call and Webcast
Teknova will host a webcast and conference call on Monday, May
13, 2024, beginning at 5:00 p.m. ET. To access the live webcast,
listeners can log onto the call from the Investor Relations section
of the Teknova website or by using this link. If you would like to
participate in the call, please register for the webcast here to
receive a unique PIN number and dial-in information. The webcast
will be available for replay on the Company’s website approximately
two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been
innovating the manufacture of critical reagents for the life
sciences industry to accelerate the discovery and development of
novel therapies that will help people live longer, healthier lives.
We offer fully customizable solutions for every stage of the
workflow, supporting industry leaders in cell and gene therapy,
molecular diagnostics, and synthetic biology. Our fast turnaround
of high-quality agar plates, microbial culture media, buffers,
reagents, and water helps our customers scale seamlessly from RUO
to GMP. Headquartered in Hollister, California, with over 200,000
square feet of state-of-the-art facilities, Teknova’s modular
manufacturing platform was designed by our team of scientists,
engineers, and quality control experts to efficiently produce the
foundational ingredients for the discovery and commercialization of
novel therapies.
Non-GAAP Financial Measures
This press release contains financial measures that have not
been calculated in accordance with U.S. generally accepted
accounting principles (GAAP). Teknova uses the following non-GAAP
financial measures in assessing the performance of its business and
the effectiveness of its business strategies: (a) Adjusted EBITDA
and (b) Free Cash Flow.
Teknova defines Adjusted EBITDA as net loss adjusted for
interest income (expense), net, provision for (benefit from) income
taxes, depreciation expense, amortization of intangible assets, and
stock-based compensation expense. Adjusted EBITDA reflects further
adjustments to eliminate the impact of certain items, including
certain non-cash and other items that Teknova does not consider
representative of its ongoing operating performance.
Teknova defines Free Cash Flow as cash used in operating
activities plus purchases of property, plant, and equipment.
Teknova provides Adjusted EBITDA and Free Cash Flow in this
press release because Teknova believes that analysts, investors,
and other interested parties frequently use these measures to
evaluate companies in Teknova’s industry and that such measures
facilitate comparisons on a consistent basis across reporting
periods. Teknova also believes such measures are helpful in
highlighting trends in Teknova’s operating results because they
exclude items that are not indicative of Teknova’s core operating
performance. Investors should consider non-GAAP financial measures
in addition to, and not as a substitute for, or as superior to,
measures of financial performance prepared in accordance with GAAP.
The non-GAAP financial measures presented by Teknova may be
different from the non-GAAP financial measures used by other
companies.
A full reconciliation of these non-GAAP measures to the most
comparable GAAP measures is included at the end of this
release.
Forward-Looking Statements
Statements in this press release about future expectations,
plans, and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements.” These statements include, but are not
limited to, statements relating to Teknova’s anticipated total
revenue, including our expectations for 2024 revenue and free cash
outflow guidance, expected growth in Lab Essentials and Clinical
Solutions, and other statements about Teknova’s business prospects,
including about the Company’s profitability, strategy of managing
operating expenses, and long-term growth strategy. The words,
without limitation, “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would,” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these or similar identifying words. These forward-looking
statements are based on management’s current expectations and
beliefs and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond Teknova’s
control and could cause actual results to differ materially and
adversely from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to,
demand for Teknova’s products (including the potential delay to or
pausing of customer orders); Teknova’s assessment of fundamental
indicators of future demand across its target customer base;
Teknova’s cash flows and revenue growth rate; Teknova’s supply
chain, sourcing, manufacturing, and warehousing; inventory
management; risks related to global economic and marketplace
uncertainties, including those related to the conflicts in Ukraine
and the Middle East; reliance on a limited number of customers for
a high percentage of Teknova’s revenue; potential acquisitions and
integration of other companies; and other factors discussed in the
“Risk Factors” section of Teknova’s most recent periodic reports
filed with the Securities and Exchange Commission (“SEC”),
including in Teknova’s Annual Report on Form 10-K for the year
ended December 31, 2023, and subsequent Quarterly Reports on Form
10-Q filed with the SEC, all of which you may obtain for free on
the SEC’s website at www.sec.gov. Although Teknova believes that
the expectations reflected in its forward-looking statements are
reasonable, Teknova does not know whether its expectations will
prove correct. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, even if subsequently made available by Teknova on its
website or otherwise. Teknova does not undertake any obligation to
update, amend, or clarify these forward-looking statements, whether
as a result of new information, future events, or otherwise, except
as may be required under applicable securities laws.
Investor ContactMatt LowellChief Financial
Officermatt.lowell@teknova.com+1 831-637-1100
Media ContactJennifer HenrySenior Vice
President, Marketingjenn.henry@teknova.com+1 831-313-1259
ALPHA TEKNOVA, INC.Condensed Statements of
Operations(Unaudited)(In
thousands, except share and per share data) |
|
|
|
For the Three Months Ended March
31, |
|
|
|
2024 |
|
|
2023 |
|
Revenue |
|
$ |
9,290 |
|
|
$ |
9,121 |
|
Cost of
sales |
|
|
7,081 |
|
|
|
6,698 |
|
Gross
profit |
|
|
2,209 |
|
|
|
2,423 |
|
Operating expenses: |
|
|
|
|
|
|
Research and development |
|
|
860 |
|
|
|
1,395 |
|
Sales and marketing |
|
|
1,667 |
|
|
|
2,343 |
|
General and administrative |
|
|
7,381 |
|
|
|
7,345 |
|
Amortization of intangible assets |
|
|
287 |
|
|
|
286 |
|
Total operating expenses |
|
|
10,195 |
|
|
|
11,369 |
|
Loss
from operations |
|
|
(7,986 |
) |
|
|
(8,946 |
) |
Other
(expenses) income, net |
|
|
|
|
|
|
Interest (expense) income, net |
|
|
(145 |
) |
|
|
93 |
|
Other income, net |
|
|
— |
|
|
|
18 |
|
Total other (expenses) income, net |
|
|
(145 |
) |
|
|
111 |
|
Loss
before income taxes |
|
|
(8,131 |
) |
|
|
(8,835 |
) |
Benefit from income taxes |
|
|
(34 |
) |
|
|
(18 |
) |
Net
loss |
|
$ |
(8,097 |
) |
|
$ |
(8,817 |
) |
Net loss
per share—basic and diluted |
|
$ |
(0.20 |
) |
|
$ |
(0.31 |
) |
Weighted
average shares used in computing net loss per share—basic and
diluted |
|
|
40,804,885 |
|
|
|
28,181,457 |
|
|
|
|
|
|
|
|
|
|
ALPHA TEKNOVA, INC.Condensed Balance
Sheets(Unaudited)(In
thousands) |
|
|
|
As of March 31, |
|
|
As of December 31, |
|
|
|
2024 |
|
|
2023 |
|
ASSETS |
|
|
|
|
|
|
Current
assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
21,596 |
|
|
$ |
28,484 |
|
Accounts receivable, net |
|
|
4,560 |
|
|
|
3,948 |
|
Inventories, net |
|
|
11,207 |
|
|
|
11,594 |
|
Prepaid expenses and other current assets |
|
|
1,460 |
|
|
|
1,634 |
|
Total current assets |
|
|
38,823 |
|
|
|
45,660 |
|
Property, plant, and equipment, net |
|
|
48,907 |
|
|
|
50,364 |
|
Operating right-of-use lease assets |
|
|
17,400 |
|
|
|
16,472 |
|
Intangible assets, net |
|
|
13,952 |
|
|
|
14,239 |
|
Other
non-current assets |
|
|
1,735 |
|
|
|
1,852 |
|
Total assets |
|
$ |
120,817 |
|
|
$ |
128,587 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
1,543 |
|
|
$ |
1,493 |
|
Accrued liabilities |
|
|
3,574 |
|
|
|
5,579 |
|
Current portion of operating lease liabilities |
|
|
1,922 |
|
|
|
1,803 |
|
Total current liabilities |
|
|
7,039 |
|
|
|
8,875 |
|
Deferred
tax liabilities |
|
|
884 |
|
|
|
919 |
|
Other
accrued liabilities |
|
|
78 |
|
|
|
102 |
|
Long-term debt, net |
|
|
13,178 |
|
|
|
13,251 |
|
Long-term operating lease liabilities |
|
|
16,260 |
|
|
|
15,404 |
|
Total liabilities |
|
|
37,439 |
|
|
|
38,551 |
|
Stockholders’ equity: |
|
|
|
|
|
|
Preferred stock |
|
|
— |
|
|
|
— |
|
Common stock |
|
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
|
183,261 |
|
|
|
181,822 |
|
Accumulated deficit |
|
|
(99,883 |
) |
|
|
(91,786 |
) |
Total stockholders’ equity |
|
|
83,378 |
|
|
|
90,036 |
|
Total liabilities and stockholders’ equity |
|
$ |
120,817 |
|
|
$ |
128,587 |
|
|
|
|
|
|
|
|
|
|
ALPHA TEKNOVA, INC.Condensed Statements of
Cash Flows (Unaudited)(In
thousands) |
|
|
|
For the Three Months Ended March
31, |
|
|
|
2024 |
|
|
2023 |
|
Operating activities: |
|
|
|
|
|
|
Net loss |
|
$ |
(8,097 |
) |
|
$ |
(8,817 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
|
|
Bad debt expense |
|
|
7 |
|
|
|
2 |
|
Inventory reserve |
|
|
(91 |
) |
|
|
(144 |
) |
Depreciation and amortization |
|
|
1,636 |
|
|
|
1,130 |
|
Stock-based compensation |
|
|
1,307 |
|
|
|
1,010 |
|
Deferred taxes |
|
|
(35 |
) |
|
|
(19 |
) |
Amortization of debt financing costs |
|
|
84 |
|
|
|
90 |
|
Non-cash lease expense |
|
|
47 |
|
|
|
47 |
|
Loss on disposal of property, plant, and equipment |
|
|
49 |
|
|
|
— |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
Accounts receivable |
|
|
(619 |
) |
|
|
(518 |
) |
Inventories |
|
|
478 |
|
|
|
240 |
|
Prepaid expenses and other current assets |
|
|
174 |
|
|
|
271 |
|
Other non-current assets |
|
|
117 |
|
|
|
102 |
|
Accounts payable |
|
|
133 |
|
|
|
(386 |
) |
Accrued liabilities |
|
|
(1,724 |
) |
|
|
(670 |
) |
Other |
|
|
(24 |
) |
|
|
(22 |
) |
Cash used in operating activities |
|
|
(6,558 |
) |
|
|
(7,684 |
) |
Investing activities: |
|
|
|
|
|
|
Proceeds
from sale of property, plant, and equipment |
|
|
125 |
|
|
|
— |
|
Purchases of property, plant, and equipment |
|
|
(112 |
) |
|
|
(4,312 |
) |
Cash provided by (used in) investing activities |
|
|
13 |
|
|
|
(4,312 |
) |
Financing activities: |
|
|
|
|
|
|
Proceeds
from equity financing, net |
|
|
(37 |
) |
|
|
— |
|
Repayment of financed insurance premiums |
|
|
(306 |
) |
|
|
— |
|
Payment
of at-the-market facility costs |
|
|
— |
|
|
|
(34 |
) |
Proceeds
from exercise of stock options |
|
|
— |
|
|
|
9 |
|
Cash used in financing activities |
|
|
(343 |
) |
|
|
(25 |
) |
Change
in cash and cash equivalents |
|
|
(6,888 |
) |
|
|
(12,021 |
) |
Cash and
cash equivalents at beginning of period |
|
|
28,484 |
|
|
|
42,236 |
|
Cash and
cash equivalents at end of period |
|
$ |
21,596 |
|
|
$ |
30,215 |
|
|
|
|
|
|
|
|
|
|
ALPHA TEKNOVA, INC.Reconciliation of
Non-GAAP Measures to the Most Comparable GAAP
Measures(Unaudited)(In
thousands) |
|
|
|
For the Three Months Ended March
31, |
|
|
|
2024 |
|
|
2023 |
|
Net loss – as reported |
|
$ |
(8,097 |
) |
|
$ |
(8,817 |
) |
Add back: |
|
|
|
|
|
|
Interest (expense) income, net |
|
|
(145 |
) |
|
|
93 |
|
Benefit from income taxes |
|
|
(34 |
) |
|
|
(18 |
) |
Depreciation expense |
|
|
1,349 |
|
|
|
844 |
|
Amortization of intangible assets |
|
|
287 |
|
|
|
286 |
|
EBITDA |
|
$ |
(6,350 |
) |
|
$ |
(7,798 |
) |
Other and non-recurring
expenses: |
|
|
|
|
|
|
Stock-based compensation expense |
|
|
1,307 |
|
|
|
1,010 |
|
Severance pay and other termination benefits |
|
|
1,287 |
|
|
|
725 |
|
Adjusted
EBITDA |
|
$ |
(3,756 |
) |
|
$ |
(6,063 |
) |
|
|
For the Three Months Ended March
31, |
|
|
|
2024 |
|
|
2023 |
|
Cash used in operating activities |
|
$ |
(6,558 |
) |
|
$ |
(7,684 |
) |
Purchases of property, plant,
and equipment |
|
|
(112 |
) |
|
|
(4,312 |
) |
Free Cash
Flow |
|
$ |
(6,670 |
) |
|
$ |
(11,996 |
) |
|
|
|
|
|
|
|
|
|
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Dec 2024 to Jan 2025
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Jan 2024 to Jan 2025